In October, OneOncology acquired United Urology Group (UUG), a leading specialty MSO supporting approximately 250 providers across five major markets. OneOncology conducted extensive financial, clinical, and cultural diligence among the leading urology MSOs and prioritized UUG due to the strong alignment with OneOncology’s key priorities. UUG brings complementary physician leadership, including nationally preeminent prostate and bladder cancer researchers.

Operationally, UUG’s track record is unparalleled among Urology MSOs, with demonstrated excellence across several critical ancillaries that are essential for comprehensive patient care and practice financial performance. These include ASCs, Radiation Oncology, Interventional Radiology (IR), Pathology, and Care Management. The combination of this physician leadership and operational excellence creates a platform uniquely able to drive value to physicians, with demonstrated improvements to physician financial outcomes across all the United Urology Group practice affiliates. UUG stands alone among urology MSOs in this aspect of their track record. The same clinical and operational proficiency that drove UUG’s success as a standalone company presents a multitude of exciting growth opportunities when combined with OneOncology’s cancer care expertise, leading independent practice footprint, and access to the capital and support of our investors, TPG and Cencora.

Cancer care and urology are becoming increasingly interdependent, with emerging technologies such as radiopharmaceuticals, antibody drug conjugates, intra-vesical drug-device delivery mechanisms, and precision therapies. Between 2023 and 2030, the global market is expected to grow from $14 billion to $26 billion for prostate cancer therapeutics and from $5 billion to $17 billion for bladder cancer therapeutics¹. This convergence has already led many large independent urology and oncology practices to evaluate expansion into the adjacent specialty. Indeed, UUG and OneOncology practices were already at various stages along this evaluation and execution journey before the transaction was completed. Now these improvements to patient care will be rapidly accelerated. Shortly after the UUG transaction, OneOncology’s partner practice, Mary Bird Perkins Cancer Center, announced the opening of a new urologic oncology clinic in Metairie, Louisiana. In December, OneOncology’s partner practice, Astera Cancer Care, added a group of six urologists. New York Cancer & Blood Specialists already support a large urology presence. In partnership with these groups, UUG and OneOncology’s leadership team will evaluate opportunities to add ancillaries such as ASCs, IR, and Care Management, while evaluating other urology expansion opportunities across the platform.

Similarly, for its urology platform, OneOncology will leverage capital and expertise to bring more leading independent urology practices onto the platform and to grow UUG’s existing practice footprint. Already, urology leaders across the country have reached out eager to hear the UUG and OneOncology combined story now that UUG has capital to resume the growth of its network. UUG’s distinguished track record and the synergies with medical oncology are resonating across the market and rapid growth of the UUG footprint is anticipated. Within existing partner practices, OneOncology will work to enhance practices’ pharmacy and infusion services and grow the scope of innovative treatments these practices offer. Moreover, the capital that OneOncology brings enables UUG to accelerate the expansion of new offices and ancillary services. OneOncology’s UUG acquisition represents another example of our physician leadership “skating where the puck is heading,” in this instance the convergence of urologic and cancer care, to provide improved patient access and practice financial performance.

¹ Pfizer Oncology Innovation Day Investor presentation, February 29, 2023.